Tumor
New anticancer drugs account for over 30% of the portfolio. New therapies include ADCs, immunotherapy, cell therapy, and more, with a robust pipeline.
Tumor
INTRODUCTION
Cancer poses a major challenge to global public health, claiming millions of lives annually. With diverse types including solid tumors and hematologic malignancies, it imposes significant psychological and financial burdens on patients and their families.
The Boji Pharmaceuticals operations management team possesses extensive experience in oncology clinical trials, having participated in studies involving multiple targets such as BTKi, EGFR, ALK, PARP, Her2, CD20, CD19, VEGFR, and others, including monoclonal and multi-clonal antibodies.
Clinical Research Project Experience
- Esophageal cancer
- Lung cancer
- Prostate cancer
- Hematologic malignancies
- Lymphoma
PROJECT EXPERIENCE
Solid tumor
Esophageal cancer, lung cancer, prostate cancer, etc.
Hematologic malignancies
Possesses extensive expertise in hematologic malignancies and lymphomas, having conducted over 100 pivotal clinical trials for diffuse large B-cell lymphoma (DLBCL).
Clinical Trials of Radiation Injury Medications
We also possess extensive experience in conducting clinical trials for drugs targeting radiation-induced damage caused by radiotherapy for tumors. We are committed to alleviating the side effects of treatment for cancer patients and improving their quality of life.
Specialized Therapies and Combination Trials
We have also accumulated significant experience in combined drug-device trials, tumor treatment using radioactive pharmaceuticals such as protons and neutrons, and photosensitizing drugs, demonstrating our commitment to continuous innovation and exploration of novel therapeutic approaches. We have operated China's first carbon ion therapy system and conducted clinical research on multiple proton and heavy ion systems.